Thymidine Kinase 1 Biomarker for DLBCL Prognostic Index
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prognostic indices for diffuse large B-cell lymphoma (DLBCL) lack accuracy in patient stratification, as they rely on parameters like lactate dehydrogenase (LDH) that may not adequately predict outcomes, necessitating the exploration of alternative biomarkers for improved risk assessment.
Innovation Solution
Incorporating thymidine kinase 1 (TK-1) levels into prognostic indices, along with extranodal disease status and Ann Arbor stage, to enhance the predictive capability of patient stratification by replacing LDH and improving the accuracy of risk scoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If lactate dehydrogenase (LDH) is used as a biomarker in prognostic indices, then the current standard for patient stratification is maintained, but the accuracy and reliability of risk assessment is insufficient
Solution Approach 1:
The invention changes the biomarker parameter from LDH to thymidine kinase 1 (TK-1), demonstrating superior prognostic value through statistical analysis. TK-1 shows higher hazard ratios and better discriminatory power in risk stratification, directly improving measurement precision and reliability of patient prognostication
Solution Approach 2:
The invention substitutes the traditional LDH biomarker system with a TK-1-based system. This replacement is supported by evidence that TK-1 levels provide more accurate prediction of survival outcomes and treatment response, effectively replacing the inadequate LDH measurement system
2Ease of operation
If existing prognostic indices are used without modification, then clinical workflow is maintained, but patient risk stratification accuracy is limited
Solution Approach 1:
The invention makes TK-1 a universal biomarker that can be integrated into multiple existing prognostic index frameworks (IPI, NCCN-IPI, etc.). TK-1 serves multiple functions: it can replace LDH in traditional indices, serve as an independent prognostic marker, and enhance risk stratification across different clinical scenarios while maintaining workflow simplicity
Solution Approach 2:
The invention merges TK-1 measurement with existing prognostic index calculations. By combining TK-1 levels with standard clinical parameters (age, stage, performance status), the invention creates enhanced composite scores that maintain the simplicity of existing workflows while dramatically improving risk assessment accuracy through multivariate analysis
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.